Supplemental Table 1. Disease codes used for patient exclusion, endpoints, or stratification analyses for Humedica (A) and THIN (B).

Transcription

1 Supplemental Table 1. Disease codes used for patient exclusion, endpoints, or stratification analyses for Humedica (A) and THIN (B). A. ICD-9 diagnosis codes in Humedica Analysis Vascular disease ICD-9 Code , 798 Stroke ICD-9 Code Coronary heart disease ICD-9 Code Respiratory disease exclusion (inc. COPD, emphysema, & asthma) ICD-9 Code Neurodegenerative disease (inc. Parkinson s & Alzheimer s Diseases) ICD-9 Code Neoplastic disease (excluding non-melanoma skin cancer) ICD-9 code n-alcoholic fatty liver disease (including NASH and NAFLD) ICD-9 code ICD-9 codes used for endpoints or stratification in the Humedica analysis n-alcoholic fatty liver disease (including NASH/NAFLD) ICD-9 code mellitus (including type 1 and type 2) ICD-9 code 25.xx B. Read codes* used in the THIN analysis Vascular disease Stroke Coronary heart disease Respiratory disease (COPD, emphysema, & asthma, excluding sinusitis) Neurodegenerative disease (inc. Parkinson s & Alzheimer s Diseases) Neoplastic disease (excluding non-melanoma skin cancer) n-alcoholic fatty liver disease (including NASH and NAFLD) Read codes used for endpoints or stratification in the THIN analysis n-alcoholic Fatty liver disease (including NASH/NAFLD) mellitus (including type 1 and type 2) *See supplemental data for specific read codes. G., G.11, G.12, G.13 G6.. G3, G3 11, G3 12, G3 13 H3.., H4.., H5.. F1 B., B.11 J61y8, J61y1 J61y8, J61y1 C1EXXX, C1FXXX Supplemental Table 2. Hazard ratios with 95% for analysis in Humedica A (data in Figure 2A) Unstratified analytical sample 95% 15 to < to <22.5 reference reference reference 22.5 to < to < to < to <

2 32.5 to < to < to < to B (data in Figure 3A) Sex stratified analysis 95% 95% 95% 15 to < to <22.5 reference reference reference to < to < to < to < to < to < to < to

3 C (data in Figure 4A) stratified analysis compared to reference within diabetes or no diabetes 95% 95% 95% 15 to < to <22.5 reference reference reference reference reference reference 22.5 to < to < to < to < to < to < to < to D (data in Figure 4B) stratified analysis compared to no diabetes reference 95% 95% 95% 15 to < to <22.5 reference reference reference to < to < to < to < to < to < to < to

4 Supplemental Table 3. Hazard ratios with 95% for analyses in THIN A (data in Figure 2B) Unstratified analytical sample 95% 15 to < to <22.5 reference reference reference 22.5 to < to < to < to < to < to < to < to B (data in Figure 3B) Sex stratified analysis 95% 95% 95% 15 to < to <22.5 reference reference reference to < to < to < to < to < to < to < to

5 C (data in Figure 4C) stratified analysis compared to reference within diabetes or no diabetes 95% 95% 95% 15 to < to <22.5 reference reference reference reference reference reference 22.5 to < to < to < to < to < to < to < to D (data in Figure 4D) stratified analysis compared to no diabetes reference 95% 95% 95% 15 to < to <22.5 reference reference reference to < to < to < to < to < to < to < to

6 15 to <2 2 to < to <25 25 to < to <3 3 to < to <35 35 to < to <4 4 to 6 Number of Patients 15 to <2 2 to < to <25 25 to < to <3 3 to < to <35 35 to < to <4 4 to 6 Number of Patients Supplemental Figure 1. Distribution of ( ) in the analytical sample for Humedica (A) and THIN (B). A Distribution for Analytical Sample in Humedica B. 25 Distribution for Analytical Sample in THIN

7 Percent Percent Supplemental Figure 2. Comparison of overweight and obesity prevalence in the analytical samples from the current study with published results. A. Distribution of overweight, obese, and extremely obese individuals in the Humedica analytical sample compared to NHANES survey (N=4674 adults ages 2-74) Humedica NHANES to <3 3 to <4 4 B. Distribution of normal weight, overweight, and obese individuals in the THIN analytical sample compared to the Health Survey for England, 212 (N=697, ages 16 and older) to <25 25 to <3 3 THIN analytical sample Health Survey for England 212